Programme Day 2

• Current and Emerging Therapies for Dyslipidemia
  Kathryn TanHong Kong, China Speaker Current and Emerging Therapies for Dyslipidemia
• Autologous Implantation of Genetically Modified Adipocytes Expressing LCAT for the Treatment of Familial LCAT Deficiency
  Koutaro YokoteJapan Speaker Autologous Implantation of Genetically Modified Adipocytes Expressing LCAT for the Treatment of Familial LCAT Deficiency
• Novel and Future Lipid-Lowering Therapy
  Sung Hee ChoiKorea Speaker Novel and Future Lipid-Lowering Therapy

• Clinical Pathways for Obesity Management
  I-Weng YenTaiwan Speaker Clinical Pathways for Obesity Management
• Anti-Obesity Medications: Clinical Use
  Kang-Chih FanTaiwan Speaker AI-driven precision drug therapy: Tailoring personalized treatment for type 2 diabetesAnti-Obesity Medications: Clinical Use
• Obesity Care in Special Populations
  Chun Heng Kuo Speaker Obesity Care in Special Populations

• Long-Term Changes of Urinary Exosomal Peptide Levels after Thyroidectomy in Patients with Thyroid Cancer: A Prospective Observational Study
  Chih-Yuan WangTaiwan Speaker Obesity 2026 updateLong-Term Changes of Urinary Exosomal Peptide Levels after Thyroidectomy in Patients with Thyroid Cancer: A Prospective Observational Study
• Salvage Radiofrequency Ablation Followed by External Beam Radiotherapy for Inoperable Recurrent Differentiated Thyroid Cancer
  Chen-Kai ChouTaiwan Speaker Salvage Radiofrequency Ablation Followed by External Beam Radiotherapy for Inoperable Recurrent Differentiated Thyroid Cancer
• Re-Differentiation Therapy in RAI-Refractory Thyroid Cancer
  Samantha Peiling YangSingapore Speaker Harnessing Molecular Diagnostics in Cytologically-Indeterminate Thyroid NodulesRe-Differentiation Therapy in RAI-Refractory Thyroid Cancer

• Sex-Specific Approaches in Precision Medicine: Advancing Endocrinology Care
  Shih-Li SuTaiwan Speaker Sex-Specific Approaches in Precision Medicine: Advancing Endocrinology CareSex differences are fundamental determinants of endocrine physiology and disease. Conventional approaches that treat men and women as biologically equivalent overlook variations in hormonal regulation, immune response, organ function, and pharmacologic metabolism. Precision medicine in endocrinology integrates these sex-specific biological and environmental factors to achieve individualized care. Emerging evidence shows that women are more prone to autoimmune thyroid disease, prolactinoma, and osteoporosis, largely due to estrogen-enhanced immune activity and X-chromosome dosage effects. Men, by contrast, experience higher rates of hypogonadism, visceral obesity, and aggressive endocrine tumors, reflecting androgen decline and single X-chromosome vulnerability. Hormonal effects, such as menopause-related bone loss, are often reversible, whereas chromosomal influences—such as those seen in Turner and Klinefelter syndromes—are irreversible and genetically determined. Pharmacokinetic and pharmacodynamic disparities further highlight the need for sex-informed dosing. Women generally have higher CYP3A4 activity and altered drug binding via increased sex hormone–binding globulin. In Asian populations, genetic polymorphisms, including the high prevalence of BRAF^V600E^ mutations in papillary thyroid cancer and variable androgen receptor CAG repeats, demand region-specific precision strategies. Sex-specific precision endocrinology moves beyond a uniform model of care by recognizing biological sex as a key variable in disease risk and treatment response. Incorporating sex-stratified analyses, adjusted diagnostic thresholds, and personalized pharmacotherapy can enhance diagnostic accuracy and therapeutic safety. For Asia, integrating genetic and environmental diversity is essential to advance equitable, individualized endocrine care.
• From the Bedside to the Digital World: Precision Medicine in Endocrinology with Al and ICT
  Miyuki KataiJapan Speaker From the Bedside to the Digital World: Precision Medicine in Endocrinology with Al and ICT
• Precision Medicine in Diabetes: Perspectives from Asia
  Ronald MaHong Kong, China Speaker Precision Medicine in Diabetes: Perspectives from AsiaChallenging Cases in Endocrinology

• New Concept in Osteoporosis Management
  Daisuke InoueJapan Speaker New Concept in Osteoporosis Management
• Bone Fragility in Diabetes
  David LuiHong Kong Speaker Bone Fragility in Diabetes
• Metabolic Bone Disorder in Thalassemia
  Wen-Pin YangTaiwan Speaker Metabolic Bone Disorder in Thalassemia

• (TBC)
  Lee-Ming Chuang Speaker
• Research on Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus
  Chin-Hsiao TsengTaiwan Speaker Research on Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus
• (TBC)
  Wei-Shiung Yang Speaker

• Update in Osteoporosis
  Dolores ShobackUnited States Speaker Update in OsteoporosisChallenging Parathyroid Cases

• Exploring the World of Autoimmune Disease: from Genetic Manipulation to Disease Reversal
  Huey-Kang SytwuTaiwan Speaker Exploring the World of Autoimmune Disease: from Genetic Manipulation to Disease Reversal

• Key Highlights of the American Thyroid Association Thyroid and Pregnancy Guidelines
  Angela M. LeungUnited States Speaker Key Highlights of the American Thyroid Association Thyroid and Pregnancy GuidelinesThyroid Risks of Iodine Excess
• Precision Medicine in Gestational Thyroid Disease: Taking Care of Mother and Baby
  Marjorie A. RamosPhilippines Speaker Precision Medicine in Gestational Thyroid Disease: Taking Care of Mother and Baby
• Iodine Status in Pregnant Women in Taiwan
  Fan-Fen WangTaiwan Speaker Iodine Status in Pregnant Women in Taiwan

• Assessing and Managing Osteoporosis in Patients with Diabetes
  Jawl-Shan Hwang Speaker Assessing and Managing Osteoporosis in Patients with Diabetes
• Diabetes and Osteoarthritis: Metabolic Links and Clinical Implications
  Jia-Feng Chen Speaker Diabetes and Osteoarthritis: Metabolic Links and Clinical Implications
• Sarcopenia in Diabetes: Pathophysiology, Diagnosis, and Management
  Tung-Wei KaoTaiwan Speaker Sarcopenia in Diabetes: Pathophysiology, Diagnosis, and Management

• PitNET (aka Pituitary Adenomas) in Multiple Endocrine Neoplasm
  Sang Ouk ChinKorea Speaker PitNET (aka Pituitary Adenomas) in Multiple Endocrine Neoplasm
• Oncologist Perspective of NET Management
  Stephen ChanHong Kong, China Speaker Oncologist Perspective of NET Management
• Functional NET
  Shyang-Rong ShihTaiwan Speaker Functional NET

• MASLD, Neurocognitive Conditions and Dysglycemia
  Lee-Ling LimMalaysia Speaker MASLD, Neurocognitive Conditions and Dysglycemia
• MASLD and Cognitive Impairment Correlate with Diabetic Management
  Noriko Satoh-AsaharaJapan Speaker MASLD and Cognitive Impairment Correlate with Diabetic Management
• MASLD and Dementia
  Chaur-Jong HuTaiwan Speaker MASLD and Dementia

• Consensus in Pituitary Pathology: Impact after New Classification for Japan
  Naoko InoshitaJapan Speaker Consensus in Pituitary Pathology: Impact after New Classification for Japan
• The Impact of the 2022 WHO PitNET Classification to the Clinical Practitioners. Does Silence Equal Acceptance?
  Szu-Tah ChenTaiwan Speaker The Impact of the 2022 WHO PitNET Classification to the Clinical Practitioners. Does Silence Equal Acceptance?The 2022 World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors redefined pituitary adenomas as pituitary neuroendocrine tumors (PitNETs) within the International Classification of Diseases for Oncology, 3rd Edition (ICD-O/3). This change reflects updated insights into tumor biology, recognizing a spectrum of clinical behaviors beyond the traditionally benign designation. A narrative review of the WHO 2022 classification updates was conducted, focusing on their clinical, diagnostic, and epidemiologic implications for practitioners in endocrinology, neurosurgery, and oncology. The reclassification emphasizes the potential for variability in tumor aggressiveness, recurrence, and invasiveness. Clinically, this shift necessitates more careful risk stratification, closer follow-up in selected cases, and a reassessment of treatment algorithms. From a reporting perspective, ICD-O/3 alignment may affect cancer registry data and epidemiologic tracking, altering disease burden estimates. Importantly, the new terminology presents challenges in patient communication, as the label “neuroendocrine tumor” may cause undue anxiety despite the indolent nature of most PitNETs. The WHO 2022 reclassification of pituitary adenomas as PitNETs represents a significant change for clinical practice. While it enhances awareness of potential aggressive behavior, it also requires balanced application in patient care to avoid overtreatment and misperceptions. Practitioners must adapt by refining diagnostic vigilance, tailoring follow-up strategies, and delivering clear patient-centered communication.
• Consensus in Pituitary Pathology: Impact after New Classification for Korea
  Jae Sung ParkKorea (Republic of) Speaker Consensus in Pituitary Pathology: Impact after New Classification for Korea

• Brain Remodeling of Appetite Centers in Obesity - Results from Murine Omics Studies and Human Brain Imaging
  Tomohiro TanakaJapan Speaker Brain Remodeling of Appetite Centers in Obesity - Results from Murine Omics Studies and Human Brain Imaging
• Obesity Management: What's New?
  Alice KongHong Kong, China Speaker Obesity: What Clinicians Should KnowObesity Management: What's New?
• The Hidden Barrier: Understanding and Overcoming Weight Bias
  Hai-Hua ChuangTaiwan Speaker The Hidden Barrier: Understanding and Overcoming Weight Bias

• Obesity 2026 Update
  Chih-Yuan WangTaiwan Speaker Obesity 2026 updateLong-Term Changes of Urinary Exosomal Peptide Levels after Thyroidectomy in Patients with Thyroid Cancer: A Prospective Observational Study

• Incretin-Based Therapeutics: Bridging Theory and Practice, and Exploring New Horizons
  Daisuke YabeJapan Speaker Advancing toward a Cure for Diabetes: Insights from iPSC-Derived Islet Cell Transplantation TrialIncretin-Based Therapeutics: Bridging Theory and Practice, and Exploring New Horizons

• Genomic Alterations in Thyroid Cancer: Biological and Clinical Insights
  Maria E. Cabanillas Speaker Genomic Alterations in Thyroid Cancer: Biological and Clinical InsightsAnaplastic Thyroid Cancer

• (TBC)
  Lee-Ling LimMalaysia Speaker MASLD, Neurocognitive Conditions and Dysglycemia

• Thyroid Risks of Iodine Excess
  Angela M. LeungUnited States Speaker Key Highlights of the American Thyroid Association Thyroid and Pregnancy GuidelinesThyroid Risks of Iodine Excess

• Challenging Parathyroid Cases
  Dolores ShobackUnited States Speaker Update in OsteoporosisChallenging Parathyroid Cases

• Anaplastic Thyroid Cancer
  Maria E. Cabanillas Speaker Genomic Alterations in Thyroid Cancer: Biological and Clinical InsightsAnaplastic Thyroid Cancer